288 related articles for article (PubMed ID: 32480349)
1. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice.
Parthymos I; Liamis G; Dounousi E; Pentheroudakis G; Mauri D; Zarkavelis G; Florentin M
Crit Rev Oncol Hematol; 2020 Jul; 151():102979. PubMed ID: 32480349
[TBL] [Abstract][Full Text] [Related]
2. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
[TBL] [Abstract][Full Text] [Related]
3. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
4. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy Toxicities.
Sanchez K; Page DB; Urba W
Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
[TBL] [Abstract][Full Text] [Related]
6. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
7. Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer.
Sebastiani GD; Scirocco C; Galeazzi M
Autoimmun Rev; 2019 Aug; 18(8):805-813. PubMed ID: 31176871
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
9. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
Trevisani V; Iughetti L; Lucaccioni L; Predieri B
Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
[TBL] [Abstract][Full Text] [Related]
10. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
[TBL] [Abstract][Full Text] [Related]
12. Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?
Percik R; Shoenfeld Y
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101411. PubMed ID: 32278687
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.
Rambhia PH; Reichert B; Scott JF; Feneran AN; Kazakov JA; Honda K; Koon H; Gerstenblith MR
Int J Clin Oncol; 2019 Oct; 24(10):1171-1181. PubMed ID: 31321613
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy is cancer treatment with a novel side-effect profile].
Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
17. New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?
Barquín-García A; Molina-Cerrillo J; Garrido P; Garcia-Palos D; Carrato A; Alonso-Gordoa T
Eur J Intern Med; 2019 Aug; 66():1-8. PubMed ID: 31130304
[TBL] [Abstract][Full Text] [Related]
18. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
20. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
Abdel-Wahab N; Shah M; Lopez-Olivo MA; Suarez-Almazor ME
Ann Intern Med; 2018 Jan; 168(2):121-130. PubMed ID: 29297009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
